Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 934164, 9 pages
http://dx.doi.org/10.1155/2015/934164
Research Article

Treatment of Endometriosis with the GnRHa Deslorelin and Add-Back Estradiol and Supplementary Testosterone

1Center for Endometriosis Research and Treatment, Department of Reproductive Medicine, UC San Diego, 9500 Gilman Drive, No. 0633, La Jolla, CA 92093-0633, USA
2Balance Pharmaceuticals, 842 N Las Casas Avenue, Pacific Palisades, CA 90272, USA
3Genesis Center for Clinical Research, 3651 4th Avenue, San Diego, CA 92103, USA
4Genetics and IVF Institute, 3015 Williams Drive, Fairfax, VA 22031, USA
5Department of Obstetrics and Gynecology, McMaster University, 1280 Main Street West, HSC-3N52D, Hamilton, ON, Canada L8S 4K1
6Department of Preventive Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
7Division of Medical Oncology, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA

Received 30 September 2015; Accepted 16 December 2015

Academic Editor: Seiichi Saito

Copyright © 2015 Sanjay K. Agarwal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. ACOG, “Practice bulletin no. 114: management of endometriosis,” Obstetrics & Gynecology, vol. 115, pp. 1100–1109, 2010. View at Google Scholar
  2. G. M. Buck Louis, M. L. Hediger, C. M. Peterson et al., “Incidence of endometriosis by study population and diagnostic method: the ENDO study,” Fertility and Sterility, vol. 96, no. 2, pp. 360–365, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. The Practice Committee of the American Society for Reproductive Medicine, “Treatment of pelvic pain associated with endometriosis: a committee opinion,” Fertility and Sterility, vol. 101, no. 4, pp. 927–935, 2014. View at Publisher · View at Google Scholar
  4. S. K. Agarwal, C. Hamrang, M. R. Henzl, and H. L. Judd, “Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin study group,” The Journal of Reproductive Medicine, vol. 42, no. 7, pp. 413–423, 1997. View at Google Scholar · View at Scopus
  5. R. L. Barbieri, “Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment,” The Journal of Reproductive Medicine, vol. 43, no. 3, supplement, pp. 287–292, 1998. View at Google Scholar
  6. R. L. Barbieri, “Hormone treatment of endometriosis: the estrogen threshold hypothesis,” American Journal of Obstetrics and Gynecology, vol. 166, no. 2, pp. 740–745, 1992. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Donnez, M. Nisolle, F. Clerckx, F. Casanas-Roux, P. Saussoy, and S. Gillerot, “Advanced endoscopic techniques used in dysfunctional bleeding, fibroids and endometriosis, and the role of gonadotrophin-releasing hormone agonist treatment,” British Journal of Obstetrics and Gynaecology, vol. 101, no. 10, pp. 2–9, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. W. L. Heinrichs and M. R. Henzl, “Human issues and medical economics of endometriosis. Three- vs. six-month GnRH-agonist therapy,” The Journal of Reproductive Medicine, vol. 43, no. 3, supplement, pp. 299–308, 1998. View at Google Scholar
  9. R. W. Shaw, “Treatment of endometriosis,” The Lancet, vol. 340, no. 8830, pp. 1267–1271, 1992. View at Publisher · View at Google Scholar · View at Scopus
  10. C.-J. Jeng, L. Chuang, and J. Shen, “A comparison of progestogens or oral contraceptives and gonadotropin-releasing hormone agonists for the treatment of endometriosis: a systematic review,” Expert Opinion on Pharmacotherapy, vol. 15, no. 6, pp. 767–773, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. S. K. Agarwal, “Differential effects of GnRH agonist therapies: implications regarding the estrogen threshold hypothesis,” in Understanding and Managing Endometriosis: Advances in Research and Practice, A. Lemay and R. Maheux, Eds., Parthenon Publishing, 1999. View at Google Scholar
  12. C. H. Gnoth, K. Gödtke, G. Freundl, E. Godehardt, and E. Kienle, “Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists,” Gynecologic and Obstetric Investigation, vol. 47, no. 1, pp. 37–41, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. M. D. Hornstein, E. S. Surrey, G. W. Weisberg, and L. A. Casino, “Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study,” Obstetrics & Gynecology, vol. 91, no. 1, pp. 16–24, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. O. Gregoriou, S. Konidaris, N. Vitoratos, C. Papadias, I. Papoulias, and A. Chryssicopoulos, “Gonadotropin-releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial,” International Journal of Fertility and Women's Medicine, vol. 42, no. 6, pp. 406–411, 1997. View at Google Scholar · View at Scopus
  15. R. Howell, D. K. Edmonds, M. Dowsett, D. Crook, B. Lees, and J. C. Stevenson, “Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial,” Fertility and Sterility, vol. 64, no. 3, pp. 474–481, 1995. View at Google Scholar · View at Scopus
  16. A. Pickersgill, “GnRH agonists and add-back therapy: is there a perfect combination?” British Journal of Obstetrics and Gynaecology, vol. 105, no. 5, pp. 475–485, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. E. S. Surrey, “Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached?” Fertility and Sterility, vol. 71, no. 3, pp. 420–424, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. E. S. Surrey, “Steroidal and nonsteroidal ‘add-back’ therapy: extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynecologic patient,” Fertility and Sterility, vol. 64, no. 4, pp. 673–685, 1995. View at Google Scholar · View at Scopus
  19. D. Wu, M. Hu, L. Hong et al., “Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis,” Archives of Gynecology and Obstetrics, vol. 290, no. 3, pp. 513–523, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Khosla, L. J. Melton III, E. J. Atkinson, W. M. O'Fallon, G. G. Klee, and B. L. Riggs, “Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen,” The Journal of Clinical Endocrinology & Metabolism, vol. 83, no. 7, pp. 2266–2274, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. J. H. Pickar, I. Thorneycroft, and M. Whitehead, “Effects of hormone replacement therapy on the endometrium and lipid parameters: a review of randomized clinical trials, 1985 to 1995,” American Journal of Obstetrics and Gynecology, vol. 178, no. 5, pp. 1087–1099, 1998. View at Publisher · View at Google Scholar · View at Scopus
  22. J. D. Woodruff and J. H. Pickar, “Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone,” American Journal of Obstetrics and Gynecology, vol. 170, no. 5, part 1, pp. 1213–1223, 1994. View at Publisher · View at Google Scholar · View at Scopus
  23. B. S. Hurst, S. C. Gardner, K. E. Tucker, C. A. Awoniyi, and W. D. Schlaff, “Delayed oral estradiol combined with leuprolide increases endometriosis-related pain,” Journal of the Society of Laparoendoscopic Surgeons, vol. 4, no. 2, pp. 97–101, 2000. View at Google Scholar · View at Scopus
  24. S. R. Davis, M. Moreau, R. Kroll et al., “Testosterone for low libido in postmenopausal women not taking estrogen,” The New England Journal of Medicine, vol. 359, no. 19, pp. 2005–2017, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. H. L. Judd and S. S. Yen, “Serum androstenedione and testosterone levels during the menstrual cycle,” Journal of Clinical Endocrinology and Metabolism, vol. 36, no. 3, pp. 475–481, 1973. View at Publisher · View at Google Scholar · View at Scopus
  26. H. M. Behre, S. Kliesch, E. Leifke, T. M. Link, and E. Nieschlag, “Long-term effect of testosterone therapy on bone mineral density in hypogonadal men,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 8, pp. 2386–2390, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Dupont, P. Dupont, A. Belanger, J. Mailoux, L. Cusan, and F. Labrie, “Hormonal and biochemical changes during treatment of endometriosis with the luteinizing hormone-releasing hormone (LH-RH) agonist [D-Trp6,des-Gly-NH2(10)]LH-RH ethylamide,” Fertility and Sterility, vol. 54, no. 2, pp. 227–232, 1990. View at Google Scholar
  28. H. G. Burger, J. Hailes, M. Menelaus, J. Nelson, B. Hudson, and N. Balazs, “The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormonal results,” Maturitas, vol. 6, no. 4, pp. 351–358, 1984. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Farish, C. D. Fletcher, D. M. Hart, F. A. Azzawi, H. I. Abdalla, and C. E. Gray, “The effects of hormone implants on serum lipoproteins and steroid hormones in bilaterally oophorectomised women,” Acta Endocrinologica, vol. 106, no. 1, pp. 116–120, 1984. View at Google Scholar · View at Scopus
  30. J. C. Montgomery, M. Brincat, A. Tapp et al., “Effect of oestrogen and testosterone implants on psychological disorders in the climacteric,” The Lancet, vol. 329, no. 8528, pp. 297–299, 1987. View at Publisher · View at Google Scholar · View at Scopus
  31. B. B. Sherwin and M. M. Gelfand, “The role of androgen in the maintenance of sexual functioning in oophorectomized women,” Psychosomatic Medicine, vol. 49, no. 4, pp. 397–409, 1987. View at Publisher · View at Google Scholar · View at Scopus
  32. Novartis Pharmaceuticals Corporation, Estraderm Human Prescription Drug Label, Novartis Pharmaceuticals Corporation, 2007, Dailymed, http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83b78f99-df2e-46c5-b308-03bac56a8c8f.
  33. S. R. Weiss, H. Ellman, and M. Dolker, “A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. Transdermal Estradiol Investigator Group,” Obstetrics & Gynecology, vol. 94, no. 3, pp. 330–336, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. P. D. Delmas, B. Pornel, D. Felsenberg et al., “A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group,” Bone, vol. 24, no. 5, pp. 517–523, 1999. View at Google Scholar
  35. E. Y. Adashi, “The climacteric ovary as a functional gonadotropin-driven androgen-producing gland,” Fertility and Sterility, vol. 62, no. 1, pp. 20–27, 1994. View at Google Scholar · View at Scopus
  36. H. Kröger, P. Vainio, J. Nieminen, and A. Kotaniemi, “Comparison of different models for interpreting bone mineral density measurements using DXA and MRI technology,” Bone, vol. 17, no. 2, pp. 157–159, 1995. View at Publisher · View at Google Scholar · View at Scopus
  37. K. O. Biberoglu and S. J. Behrman, “Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness,” American Journal of Obstetrics and Gynecology, vol. 139, no. 6, pp. 645–654, 1981. View at Google Scholar · View at Scopus
  38. J. E. Ware Jr. and C. D. Sherbourne, “The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection,” Medical Care, vol. 30, no. 6, pp. 473–483, 1992. View at Publisher · View at Google Scholar · View at Scopus
  39. P. A. Ganz, R. Day, J. E. Ware Jr., C. Redmond, and B. Fisher, “Base-line quality-of-life assessment in the national surgical adjuvant breast and bowel project breast cancer prevention trial,” Journal of the National Cancer Institute, vol. 87, no. 18, pp. 1372–1382, 1995. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Newton, D. Slota, I. S. Tummon, and A. A. Yuzpe, “Memory complaints associated with the use of gonadotropin-releasing hormone agonists: a preliminary study,” Fertility and Sterility, vol. 65, no. 6, pp. 1253–1255, 1996. View at Google Scholar · View at Scopus
  41. C. Newton, D. Slota, A. A. Yuzpe, and I. S. Tummon, “Memory complaints associated with the use of gonadotropin-releasing hormone agonists: a preliminary study,” Fertility and Sterility, vol. 65, no. 6, pp. 1253–1255, 1996. View at Google Scholar · View at Scopus
  42. C. Jenkinson, A. Coulter, and L. Wright, “Short form 36 (SF 36) health survey questionnaire: normative data for adults of working age,” British Medical Journal, vol. 306, no. 6890, pp. 1437–1440, 1993. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Vercellini, L. Fedele, G. Aimi, G. Pietropaolo, D. Consonni, and P. G. Crosignani, “Association between endometriosis stage, lesion type, patient characteristics and severity of pelvic pain symptoms: a multivariate analysis of over 1000 patients,” Human Reproduction, vol. 22, no. 1, pp. 266–271, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Brown and C. Farquhar, “Endometriosis: an overview of Cochrane reviews,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD009590, pp. 1–43, 2014. View at Publisher · View at Google Scholar
  45. A. D. DiVasta, H. A. Feldman, J. Sadler Gallagher et al., “Hormonal add-back therapy for females treated with gonadotropin-releasing hormone agonist for endometriosis: a randomized controlled trial,” Obstetrics & Gynecology, vol. 126, no. 3, pp. 617–627, 2015. View at Publisher · View at Google Scholar
  46. D. Wu, M. Hu, L. Hong et al., “Clinical efficacy of add-back therapy in treatment of endometriosis: A meta-analysis,” Archives of Gynecology and Obstetrics, vol. 290, no. 3, pp. 513–523, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. Z. Blumenfeld, G. Katz, and A. Evron, “‘An ounce of prevention is worth a pound of cure’: the case for and against GnRH-agonist for fertility preservation,” Annals of Oncology, vol. 25, no. 9, Article ID mdu036, pp. 1719–1728, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. P. D. Simpson, J. S. McLaren, J. Rymer, and E. P. Morris, “Minimising menopausal side effects whilst treating endometriosis and fibroids,” Post Reproductive Health, vol. 21, no. 1, pp. 16–23, 2015. View at Publisher · View at Google Scholar
  49. K. Chwalisz, E. Surrey, and F. Z. Stanczyk, “The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis,” Reproductive Sciences, vol. 19, no. 6, pp. 563–571, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Fooladi, R. J. Bell, F. Jane, P. J. Robinson, J. Kulkarni, and S. R. Davis, “Testosterone improves antidepressant-emergent loss of libido in women: findings from a randomized, double-blind, placebo-controlled trial,” Journal of Sexual Medicine, vol. 11, no. 3, pp. 831–839, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. S. R. Davis and G. D. Braunstein, “Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women,” Journal of Sexual Medicine, vol. 9, no. 4, pp. 1134–1148, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. N. Y. Kim, U. Ryoo, D.-Y. Lee, M. J. Kim, B.-K. Yoon, and D. Choi, “The efficacy and tolerability of short-term low-dose estrogen-only add-back therapy during post-operative GnRH agonist treatment for endometriosis,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 154, no. 1, pp. 85–89, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Furness, H. Roberts, J. Marjoribanks, and A. Lethaby, “Hormone therapy in postmenopausal women and risk of endometrial hyperplasia,” Cochrane Database of Systematic Reviews, vol. 8, Article ID CD000402, 2012. View at Publisher · View at Google Scholar
  54. K. L. Wisner, D. K. Y. Sit, E. L. Moses-Kolko et al., “Transdermal estradiol treatment for postpartum depression: a pilot, randomized trial,” Journal of Clinical Psychopharmacology, vol. 35, pp. 389–395, 2015. View at Google Scholar
  55. J. Kulkarni, E. Gavrilidis, W. Wang et al., “Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age,” Molecular Psychiatry, vol. 20, pp. 695–702, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. X. Lucas, “Clinical use of deslorelin (GnRH agonist) in companion animals: a review,” Reproduction in Domestic Animals, vol. 49, supplement 4, pp. 64–71, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Kuhl, “Pharmacology of estrogens and progestogens: influence of different routes of administration,” Climacteric, vol. 8, supplement 1, pp. 3–63, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. S. R. Davis and S. L. Davison, “Current perspectives on testosterone therapy for women,” Menopausal Medicine, vol. 2, pp. S1–S4, 2012. View at Google Scholar